2022 - Research.com Best Scientist Award
His primary scientific interests are in Cancer research, Lung cancer, Tumor suppressor gene, Molecular biology and Cancer. John D. Minna interconnects DNA methylation, Carcinogenesis, Gene, Mutation and Loss of heterozygosity in the investigation of issues within Cancer research. His Lung cancer research is included under the broader classification of Pathology.
John D. Minna has researched Tumor suppressor gene in several fields, including Breast cancer, Angiogenesis, Epigenetics and PTEN. His Molecular biology study also includes
John D. Minna spends much of his time researching Cancer research, Lung cancer, Cancer, Molecular biology and Internal medicine. John D. Minna has researched Cancer research in several fields, including Cell, Cell culture, Carcinogenesis, Tumor suppressor gene and KRAS. The concepts of his Tumor suppressor gene study are interwoven with issues in DNA methylation and Loss of heterozygosity.
His Lung cancer study necessitates a more in-depth grasp of Pathology. His work carried out in the field of Molecular biology brings together such families of science as Gene expression, Gene and Cell growth. His Internal medicine study combines topics in areas such as Gastroenterology, Endocrinology and Oncology.
His primary areas of investigation include Cancer research, Lung cancer, Cancer, KRAS and Cancer cell. His research investigates the link between Cancer research and topics such as Cell culture that cross with problems in Gene expression. His Lung cancer research integrates issues from Computational biology and Adenocarcinoma.
His Cancer study typically links adjacent topics like Growth inhibition. His KRAS research incorporates themes from Molecular biology, Mutant, Gene knockdown and MAPK/ERK pathway. As a part of the same scientific study, John D. Minna usually deals with the Cancer cell, concentrating on Cell biology and frequently concerns with Microvesicles.
John D. Minna focuses on Cancer research, Lung cancer, Cancer, Cancer cell and Adenocarcinoma. His Cancer research study combines topics from a wide range of disciplines, such as Cell growth, NEUROD1, ASCL1, Oncogene and KRAS. His study in Oncogene is interdisciplinary in nature, drawing from both Molecular biology and Cell culture.
His Molecular biology research is multidisciplinary, relying on both Mutation and EZH2. His work deals with themes such as Epithelial–mesenchymal transition, Immunology and Bioinformatics, which intersect with Lung cancer. His Cancer study incorporates themes from Growth inhibition, Telomerase, In vivo and Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Detection and Isolation of Type C Retrovirus Particles From Fresh and Cultured Lymphocytes of a Patient With Cutaneous T-cell Lymphoma
Bernard J. Poiesz;Francis W. Ruscetti;Adi F. Gazdar;Paul A. Bunn.
Proceedings of the National Academy of Sciences of the United States of America (1980)
Evaluation of a Tetrazolium-based Semiautomated Colorimetric Assay: Assessment of Chemosensitivity Testing
James Carmichael;William G. DeGraff;Adi F. Gazdar;John D. Minna.
Cancer Research (1987)
Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
Hisayuki Shigematsu;Hisayuki Shigematsu;Li Lin;Takao Takahashi;Masaharu Nomura.
Journal of the National Cancer Institute (2005)
Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer.
Frank Cuttitta;Desmond N. Carney;James Mulshine;Terry W. Moody.
p53: a frequent target for genetic abnormalities in lung cancer
Takashi Takahashi;Marion M. Nau;Itsuo Chiba;Michael J. Birrer.
BRAF and RAS mutations in human lung cancer and melanoma
Marcia S. Brose;Patricia Volpe;Michael Feldman;Madhu Kumar.
Cancer Research (2002)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski.
Characterizing the cancer genome in lung adenocarcinoma
Barbara A. Weir;Barbara A. Weir;Michele S. Woo;Gad Getz;Sven Perner;Sven Perner.
A small-cell lung cancer genome with complex signatures of tobacco exposure
Erin D. Pleasance;Philip J. Stephens;Sarah O’Meara;Sarah O’Meara;David J. McBride.
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas;Alissa C. Baker;Ralph M. DeBiasi;Ralph M. DeBiasi;Wendy Winckler;Wendy Winckler.
Nature Genetics (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: